CN1726393B - 用于检测癌症及其前体病变的化合物和方法 - Google Patents

用于检测癌症及其前体病变的化合物和方法 Download PDF

Info

Publication number
CN1726393B
CN1726393B CN2003801065094A CN200380106509A CN1726393B CN 1726393 B CN1726393 B CN 1726393B CN 2003801065094 A CN2003801065094 A CN 2003801065094A CN 200380106509 A CN200380106509 A CN 200380106509A CN 1726393 B CN1726393 B CN 1726393B
Authority
CN
China
Prior art keywords
cancer
dnase
polypeptide
cell
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2003801065094A
Other languages
English (en)
Chinese (zh)
Other versions
CN1726393A (zh
Inventor
约翰内斯·科伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1726393A publication Critical patent/CN1726393A/zh
Application granted granted Critical
Publication of CN1726393B publication Critical patent/CN1726393B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
CN2003801065094A 2002-12-18 2003-12-16 用于检测癌症及其前体病变的化合物和方法 Expired - Fee Related CN1726393B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02102814A EP1431762B1 (en) 2002-12-18 2002-12-18 Compounds and methods for detection of carcinomas and their precursor lesions
EP02102814.7 2002-12-18
PCT/EP2003/051028 WO2004055514A1 (en) 2002-12-18 2003-12-16 Compounds and methods for detection of carcinomas and their precursor lesions

Publications (2)

Publication Number Publication Date
CN1726393A CN1726393A (zh) 2006-01-25
CN1726393B true CN1726393B (zh) 2010-04-28

Family

ID=32338157

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2003801065094A Expired - Fee Related CN1726393B (zh) 2002-12-18 2003-12-16 用于检测癌症及其前体病变的化合物和方法

Country Status (10)

Country Link
US (2) US20060121485A1 (https=)
EP (1) EP1431762B1 (https=)
JP (1) JP4527544B2 (https=)
CN (1) CN1726393B (https=)
AT (1) ATE360817T1 (https=)
AU (1) AU2003302964A1 (https=)
CA (1) CA2510150C (https=)
DE (1) DE60219809T2 (https=)
ES (1) ES2286201T3 (https=)
WO (1) WO2004055514A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60219809T2 (de) * 2002-12-18 2008-01-17 Coy, Johannes F., Dr. Verbindungen und Verfahren zur Nachweiss von Karzinomen und deren Vorstufen
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US9248166B2 (en) * 2003-07-14 2016-02-02 Cls Therapeutics Limited Method for treating oncological diseases
EP2416156B1 (en) 2006-10-18 2015-12-30 Periness Ltd. Method for determining a male fertility status
JP2008253188A (ja) * 2007-04-04 2008-10-23 Tokyo Univ Of Science エンドサイトーシス依存性ｄｎａ取り込み抑制剤、エンドサイトーシス依存性ｄｎａ取り込み促進剤、ウイルス感染阻害剤、ウイルス感染予防剤、及びウイルス感染促進剤、並びに、遺伝子マーカー、モノクローナル抗体、ハイブリドーマ、及びそれらの使用方法。
US7734161B2 (en) * 2007-04-19 2010-06-08 Avago Technologies Ecbu Ip (Singapore) Pte. Ltd. Image stabilization with adaptive shutter control
US9360489B2 (en) 2007-06-11 2016-06-07 Sutter Bay Hospitals Method and kit for dynamic gene expression monitoring
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
CN104267011A (zh) * 2014-09-23 2015-01-07 中国科学院东北地理与农业生态研究所 一种转基因羊卵母细胞的筛选方法
ES2799515T3 (es) 2015-05-22 2020-12-18 Dmitry Dmitrievich Genkin ADN extracelular como una diana terapéutica en la neurodegeneración
CN107677823A (zh) * 2016-08-02 2018-02-09 北京金沐医疗科技有限公司 一种用于检测肿瘤抗原的蛋白芯片试剂盒及其检测方法
CN107677822A (zh) * 2016-08-02 2018-02-09 北京金沐医疗科技有限公司 检测肿瘤标志物的荧光细胞计数检测试剂盒
CN107677820A (zh) * 2016-08-02 2018-02-09 北京金沐医疗科技有限公司 一种检测肿瘤抗原的试剂盒及其检测方法
AU2019209770B2 (en) 2018-01-16 2025-07-31 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
CN109406771B (zh) * 2018-10-26 2023-04-07 安徽大千生物工程有限公司 胱抑素c胶乳增强比浊法检测试剂盒及其制备使用方法
WO2020223265A1 (en) * 2019-04-28 2020-11-05 Essenlix Corporation Rapid pathology/cytology without wash
CN113314220B (zh) * 2021-07-28 2021-11-02 江苏为真生物医药技术股份有限公司 疾病病程监控系统、计算机可读存储介质以及电子设备

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19521046C1 (de) * 1995-06-09 1996-08-08 Deutsches Krebsforsch Protein mit DNase-Aktivität
WO2000052204A2 (en) * 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
EP1249495A1 (de) * 2001-04-11 2002-10-16 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Murine DNase X, diese enthaltendes Arzneimittel und nicht-menschliches Säugetier mit verändertem DNase X-Gen
MXPA04004378A (es) * 2001-11-07 2004-09-10 Univ Arkansas Diagnostico, prognosis e identificacion de objetivos terapeuticos potenciales de mieloma multiple basado en el perfilado de expresion de genes.
CA2499709A1 (en) * 2002-06-19 2003-12-31 Yoichi Furukawa Method for diagnosis of colorectal tumors
DE60219809T2 (de) * 2002-12-18 2008-01-17 Coy, Johannes F., Dr. Verbindungen und Verfahren zur Nachweiss von Karzinomen und deren Vorstufen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Daisuke Shiokawa等.Characteriazation of two DNase gama-specific monoclonalantibodies and in situ detection of DNase gama in the nucleiof apoptotic rat thymocytes.Biochemical and Biophysical Research Communications275.2000,275343-349. *
Souichi Tsutsumi et al..Association of DNase I phenotype 2 with colorectalcarcinoma risk in Janpanese populations.Cancer Letters159.2000,159109-112. *

Also Published As

Publication number Publication date
JP2006510363A (ja) 2006-03-30
AU2003302964A1 (en) 2004-07-09
WO2004055514A1 (en) 2004-07-01
ATE360817T1 (de) 2007-05-15
EP1431762B1 (en) 2007-04-25
JP4527544B2 (ja) 2010-08-18
DE60219809T2 (de) 2008-01-17
EP1431762A1 (en) 2004-06-23
DE60219809D1 (de) 2007-06-06
US20060121485A1 (en) 2006-06-08
ES2286201T3 (es) 2007-12-01
US8759004B2 (en) 2014-06-24
US20080234393A1 (en) 2008-09-25
CA2510150C (en) 2017-11-07
HK1086331A1 (zh) 2006-09-15
CN1726393A (zh) 2006-01-25
CA2510150A1 (en) 2004-07-01

Similar Documents

Publication Publication Date Title
US8759004B2 (en) Compounds and methods for detection of carcinomas and their precursor lesions
JP5713036B2 (ja) 癌の検出方法
AU2013291047B2 (en) Cancer detection method
KR20140057361A (ko) 암의 치료 및 진단을 위한 방법 및 조성물
JP2014027932A (ja) がん関連抗原
WO2014061419A1 (ja) 新規癌マーカーおよびその利用
CN100384875C (zh) 蛋白质
JP2012530725A (ja) ソリシジン由来ペプチドならびにｔｒｐｖ−６がんの検出および薬剤送達のための方法
JP2003507027A (ja) タンパク質、遺伝子ならびに乳癌の診断及び処置へのこれらの使用
KR20070073802A (ko) Ｗｎｔ 단백질 및 암의 검출 및 치료
CN101768214B (zh) 一种人肿瘤标志物-Tim17多肽及其用途
CN110305963A (zh) 一种食管癌分子标志物及其应用
JPWO2008093886A1 (ja) Ｍｃｆ７由来細胞
EP1426442A1 (en) Marker molecules associated with colorectal lesions
JP2004248575A (ja) 膵癌検出用マーカー
US6858386B1 (en) Method of diagnosing, monitoring, staging, imaging and treating colon cancer
CN105624275B (zh) Eif4g1在鳞癌诊断和治疗中的应用
EP1705487A2 (en) Method of diagnosing, monitoring, staging, imaging and treating colon cancer
JP4520848B2 (ja) 肺腫瘍に関連したマーカー分子
HK1086331B (en) Compounds and methods for detection of carcinomas and their precursor lesions
KR20140018411A (ko) Ｗｎｔ 단백질 및 암의 검출 및 치료

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1086331

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1086331

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100428

Termination date: 20111216